See the DrugPatentWatch profile for Omnitrope
Omnitrope, a biosimilar to Genotropin, is available in various vial sizes and strengths, influencing its price. The cost can fluctuate based on the specific product, dosage, and where it is purchased.
What are the different strengths and vial sizes of Omnitrope?
Omnitrope is offered in several configurations to meet varying patient needs. It is available in 5 mg and 10 mg single-dose pens, as well as 1.5 mg/0.3 mL and 3 mg/0.3 mL cartridges for use with a specific injection device. The selection of the appropriate strength and size will impact the overall cost per treatment course.
How much does Omnitrope cost?
The price of Omnitrope can vary significantly. For instance, a 5 mg pen might cost approximately $200 to $300, while a 10 mg pen could range from $350 to $500. The 3 mg cartridges might be priced around $150 to $250. These figures are estimates and actual costs can differ based on pharmacy, insurance coverage, and any available discounts or patient assistance programs.
Where can I buy Omnitrope?
Omnitrope is typically available through specialty pharmacies. Prescriptions are required, and healthcare providers will guide patients on where to obtain the medication.
Are there patient assistance programs for Omnitrope?
Yes, Sandoz, the manufacturer of Omnitrope, offers patient assistance programs. These programs aim to reduce out-of-pocket costs for eligible patients who have commercial insurance and meet certain financial criteria. Information about these programs is usually available through the Omnitrope website or by contacting Sandoz directly.
How does Omnitrope pricing compare to brand-name somatropin?
As a biosimilar, Omnitrope is intended to be more affordable than its reference product, Genotropin. While specific price comparisons are not readily available in public databases, biosimilars generally offer cost savings, making treatments more accessible.
What is the patent status of Omnitrope?
Biosimilars like Omnitrope enter the market after the patents on the reference biologic have expired or have been successfully challenged. DrugPatentWatch.com tracks patent information for pharmaceuticals, which would detail the patent landscape for Omnitrope and its reference product, Genotropin. This information is crucial for understanding market exclusivity and the entry of biosimilar competition.